Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures

AdventHealth1 site in 1 countryOctober 2013

ConditionsPancreatic Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Pancreatic Cancer
Sponsor: AdventHealth
Locations: 1
Primary Endpoint: 22 gauge needle
Status: Withdrawn
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The investigators hypothesis is that a 22 gauge needle can yield core tissue, obviating the need to use the 19 gauge needle for core tissue procurement.

Detailed Description

Inclusion Criteria 1. Age under 19 years 2. Pregnant women will be excluded. This will be confirmed by self-report Exclusion Criteria 1. Age under 19 years 2. Pregnant women will be excluded. This will be confirmed by self-report

Registry

clinicaltrials.gov

Start Date

October 2013

End Date

June 2015

Last Updated

9 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

AdventHealth

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•All patients who are referred to Florida Hospital Center for Interventional Endoscopy for a EUS FNA for core biopsy (19 gauge needle biopsy) who have needle dysfunction (This occurs in about 10% of patients)

Exclusion Criteria

•Age under 19 years
•Pregnant women will be excluded. This will be confirmed by self-report

Outcomes

Primary Outcomes

22 gauge needle

Time Frame: 72 hours

Compare the quality of core tissue specimens obtained between a 19G and 22G needle by evaluating the ability to perform molecular marker studies or immunohistochemistry studies between samples obtained.